Hyperfine Secures $40M to Expand Portable Brain Imaging Revolution

FARMINGTON, Conn. – March 23, 2026 – Health technology innovator Hyperfine, Inc. has secured a significant $40 million loan facility from Horizon Technology Finance Corporation, a key move designed to accelerate the commercial expansion of its groundbreaking portable magnetic resonance (MR) brain imaging system. The deal provides an immediate infusion of $15 million, with an additional $25 million available to fuel future growth as the company aims to make advanced neuroimaging more accessible worldwide.

Hyperfine is the developer of the Swoop® System, the first AI-powered, portable MR brain imaging system to receive FDA clearance. This funding injection comes as the company shows increasing commercial traction and clinical validation, positioning it to further disrupt the traditional landscape of diagnostic imaging, which has long been dominated by large, stationary, and costly equipment.

A New Frontier in Neuroimaging at the Point of Care

The core of Hyperfine's innovation is the Swoop® System, a device that fundamentally reimagines where and how brain imaging can be performed. Unlike conventional MRI machines that require shielded rooms and specialized infrastructure, the Swoop® system can be wheeled directly to a patient's bedside and plugs into a standard wall outlet. This portability unlocks access in critical care settings like intensive care units (ICUs) and emergency departments, as well as in smaller community hospitals and outpatient neurology offices that cannot support a traditional MRI suite.

Recent clinical data underscores the system's value. The NEURO PMR study, presented earlier this year, highlighted a superior patient experience in outpatient settings. It found patients were four times more likely to prefer the portable Swoop® system over a standard MRI, citing significant reductions in anxiety, claustrophobia, and noise. Crucially, the study also confirmed that trained clinical staff could successfully operate the system without specialized MR technologists, demonstrating its ease of use and integration into existing workflows.

Furthermore, the ACTION PMR study focused on emergency stroke care, revealing a dramatic reduction in the time-to-scan. Patients received a scan in a median time of just 2.5 hours with the Swoop® system, compared to 27.7 hours for conventional MRI. This speed is critical in stroke diagnosis, where every minute saved can impact patient outcomes. The system showed diagnostic performance comparable to head CT scans and good specificity for identifying acute strokes, proving its utility in time-sensitive situations.

“Hyperfine has built a truly differentiated technology platform that is expanding access to brain imaging in settings where conventional MRI is not accessible, practical, affordable nor readily available,” said Paul Seitz, Chief Investment Officer of Horizon, in the original announcement.

Fueling Commercial Growth Amidst a Shifting Market

The $40 million facility from Horizon is not a lifeline but rather strategic fuel for a company on an upward trajectory. Hyperfine has demonstrated consistent commercial progress, with revenues growing 62% in 2023 and continuing to climb. The company reported selling 37 Swoop® systems in 2023 and has steadily increased its placements, driven by demand from hospitals, neurology offices, and international markets following regulatory approvals in Europe, the UK, Australia, and India.

Financially, Hyperfine has made significant strides in operational efficiency. The company dramatically reduced its annual cash burn from $71 million in 2022 to $42 million in 2023 and has seen its gross margin climb consistently, recently surpassing the 50% mark. This improved financial discipline has extended its cash runway and provides a solid foundation for the new debt facility to be deployed for aggressive expansion rather than operational upkeep.

The capital will be instrumental in scaling the commercial team, expanding global reach, and driving deeper penetration into new market segments like private neurology practices. Hyperfine's second-generation scanner and its AI-driven Optive software suite, introduced in 2025, have further enhanced image quality and diagnostic capabilities, broadening the system's clinical applications.

“This facility provides us with the capital to accelerate the commercial expansion of our Swoop® System across hospital and office settings as well as globally,” noted Maria Sainz, Chief Executive Officer and President of Hyperfine. She emphasized the goal of expanding “the reach and access of MRI for acute and chronic brain conditions providing high clinical and economic value to patients, clinicians and providers.”

The Strategic Bet on Medtech Venture Debt

For Horizon Technology Finance, the investment in Hyperfine is a clear reflection of its strategy to back high-growth, innovative companies in the life sciences and technology sectors. As a provider of venture debt, Horizon offers a crucial form of capital for companies like Hyperfine that are past the early startup phase and are focused on commercial scaling. This type of financing allows companies to fund growth without the significant equity dilution that often comes with venture capital rounds.

Horizon's portfolio includes a range of medtech and life science companies, and its recent activity, such as a $50 million venture loan to dermatology innovator Pelthos Therapeutics Inc., shows a continued appetite for a sector that is both capital-intensive and rich with potential. The firm's investment thesis hinges on identifying companies with differentiated technology, strong clinical evidence, and a clear path to commercial success—a profile that Hyperfine fits well.

Seitz added that Hyperfine’s “strong clinical and economic evidence, a growing commercial opportunity with expanding sites of care, and a second-generation system that delivers diagnostic quality images” were key factors in the decision, expressing excitement to “support Hyperfine’s continued growth and the broader adoption of point-of-care neuroimaging.”

AI and Portability: Redefining Diagnostic Imaging's Future

The partnership between Hyperfine and Horizon spotlights a powerful paradigm shift in medicine: the decentralization of diagnostics, powered by the convergence of portability and artificial intelligence. For decades, advanced imaging has been a centralized resource, creating bottlenecks, delaying diagnoses, and limiting access for patients in rural or under-resourced areas. The Swoop® System is at the forefront of changing that reality.

While portable, low-field MRI systems have historically faced skepticism regarding image quality compared to their high-field counterparts, AI is proving to be the great equalizer. By leveraging sophisticated algorithms, Hyperfine’s system can process images to enhance clarity and provide diagnostic-quality information, overcoming the physical limitations of a smaller magnetic field. This AI integration is not just a feature but the enabling technology that makes point-of-care MR imaging a viable and powerful clinical tool.

Medical experts see this as a groundbreaking innovation that complements, rather than replaces, existing diagnostic tools. The ability to quickly obtain crucial information at the bedside can help clinicians triage patients more effectively, monitor conditions in real-time without moving critically ill patients, and make timely decisions that can save lives and improve long-term outcomes. As these systems become more widespread, the fusion of artificial intelligence and accessible hardware is poised to fundamentally redefine the standards of neurological care for years to come.